The company states that no adverse events have been reported due to the contamination as of yet.
Robitussin producer Haleon issued a nationwide recall for two of the brand’s products: Honey CF Max Day Adult and Honey CF Max Nighttime Adult. In a press release, the company explained that the recall is due to a microbial contamination. In total, there are eight lots being recalled.1
Both products are cough syrups used to relieve symptoms related to cold or flu infections. Both types of infections are common during the winter months, meaning that use of products like Robitussin are more likely during this time period.
According to the company’s press release, the contamination can cause serious complications for immunocompromised individuals, including life-threatening events. These events can include fungemia or disseminated fungal infections. While non-immunosuppressed users of the product are unlikely to develop life-threatening infections, the company notes that these individuals would still be at risk for infections serious enough to require medical intervention.
Fortunately, Haleon has yet to receive any reports of medical events related to this recall.
The recall includes the following lots for Robitussin Honey CF Max Day Adult 8 oz. bottles:
The recall also includes Lot Number T10810 for Robitussin Honey CF Max Day Adult 4 oz. bottles.
The following lots are included in the recall for Robitussin Honey CF Max Nighttime Adult 8 oz. bottles:
Haleon states that any consumers that may have purchased bottles from any of the listed lots should contact their consumer relations team at 1 (800) 245-1040 or email them at firstname.lastname@example.org.
The company has also contacted distributors across the country to notify them of the recall.
Haleon is an independent company that produces a variety of brands of over-the-counter medication. Its portfolio includes brands such as Advil, Centrum, Sensodyne, and TUMS. The current recall only impacts the eight lots listed in the recent press release.
Prior to 2022, Haleon was a part of GSK. The two companies demergered in July 2022. At the time, the company stated that its goal was to remove barriers to better every day health and to empower 50 million people a year by 2025 to included in opportunities for better every day health.2
At the time of the demerger, Haleon CEO Brian McNamara said in a press release, “"This is a significant milestone for Haleon. Guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive, and sustainable.”
He continued, “Consumer health has never been more important than it is today, and I am delighted that Haleon, as an independent company, is ready to pursue our ambitions. Today follows a huge amount of effort, planning, and collaboration by our dedicated colleagues all around the world."
The company’s name is a combination of the words hale, an old English word for good health, and leon, a word meaning strength.